生物制剂的临床药理计划是怎样的？
Monoclonal antibodies are now widely used in the treatment of several diseases, providing effective and…
Certara2021 年 8 月 6 日
Population Pharmacokinetics of Diethylcarbamazine in Patients with Lymphatic Filariasis and Healthy Individuals
Find out how body‑weight and sex effects on DEC PK in filariasis patients, supporting improved…
Certara2021 年 7 月 26 日
Key considerations to ensure maximal probability of antibody drug conjugate development success
Antibody drug conjugates (ADC) are a unique way to obliterate tumor cells and represent an…
Certara2021 年 7 月 8 日
Cystatin C and/or creatinine-based estimated glomerular filtration rate for prediction of vancomycin clearance in long-stay critically ill patients with persistent inflammation, immunosuppression and catabolism syndrome (PICS): a population pharmacokinetics analysis
Learn how cystatin‑C improves vancomycin clearance prediction in PICS patients, reducing variability and preventing supratherapeutic…
Certara2021 年 3 月 16 日
Population Pharmacokinetics and Dosage Optimization of Linezolid in Critically Ill Pediatric Patients
Explore how key covariates and showed higher‑frequency dosing improves linezolid target attainment in critically ill…
Certara2021 年 2 月 8 日
8 tips for successfully developing oligonucleotide therapies
By Eva Gil Berglund and Nathalie H Gosselin Oligonucleotide therapeutics are a validated class of…
Certara2021 年 2 月 1 日
“Where do I start?”: Strategies for selecting the first dose for human clinical trials
This guide to dose selection for first-in-human studies explains the conceptual framework, methods, and tools…
Certara2020 年 12 月 22 日
Using a pharmacology to payer framework to support product development
Modeling and simulation (M&S) of complex systems has primarily advanced vertically in differing scientific domains…
Certara2018 年 3 月 16 日
